Omeros (OMER) Cash on Hand per Share

Cash per share trends demonstrate Omeros Corporation (OMER) dependence on external funding due to the lack of stable cash flow. Omeros Corporation (OMER) is developing neuropharma through partnerships with scientific centers, yet faces patent risks from industry behemoths. The 1.27 level reflects current liquidity, helping investors assess the business's real margin of safety regardless of market volatility.
Comprehensive metric breakdowns and analytics for Omeros (OMER)

For Omeros Corporation (OMER), the balance between liquidity and capital efficiency is critical, especially given the total reliance on external CMOs for drug production. By analyzing the cash per share metric, which equals 1.27, an investor assesses the volume of net cash per share, which determines the financial stability of the R&D holding in the face of outsourcing operational risks.